---
topic: Primary vs Secondary Prevention Status and Actual Cardiovascular Disease Burden
status: archived-to-lpa-master
last_updated: 2026-06-03
tags: [cardiovascular, prevention-status, lp(a), archived]
priority: urgent
abstract: >-
  This former standalone prevention-status page has been folded into ASCVD / Lp(a) Prevention Master. It remains as a short preserved pointer so old links do not break.
---

# Prevention Status + CVD Burden — archived pointer

This page is no longer the active owner. Its primary-vs-secondary prevention boundary, CAC/CCTA risk-tier table, LDL/ApoB target logic, and aspirin boundary were folded into [ASCVD / Lp(a) Prevention Master](#sec-lp-a) on 2026-05-10.

Preserved core rule, updated after old papers were found: 2024 RPPH Doppler documents mild right common-femoral plaque/PAD (24-31% stenosis), so the profile is not risk-factor-only anymore; coronary/valve burden still requires CAC/CCTA/echo staging. Lp(a) this high plus peripheral plaque justifies aggressive risk-factor control and cardiology prevention review, but still not self-directed aspirin while GI bleeding risk is live.

Full original text is preserved in `archive/ascvd-lpa-prevention-originals-2026-05-10.md`.